East China Pharmaceutical: Wholly-owned subsidiary East China Pharmaceutical Hangzhou signed an exclusive commercial cooperation agreement with Jiangsu Wei Kail.

East China pharmaceutical announced that its wholly-owned subsidiary East China pharmaceutical Hangzhou signed an exclusive commercial cooperation agreement with Jiangsu weikai'er, obtaining the exclusive commercialization rights of VC005 oral dosage form in mainland China. East China pharmaceutical Hangzhou will pay a down payment of 50 million yuan to Jiangsu weikai'er, as well as milestone payments of up to 180 million yuan. VC005 tablet is a new, potent, highly selective second-generation oral JAK1 inhibitor, clinically developed for the treatment of inflammation and autoimmune diseases, and is currently in phase III clinical trials for moderate to severe atopic eczema.